Abstracts

Severity Assessment in CDKL5 Deficiency Disorder

Abstract number : 1.389
Submission category : 12. Genetics / 12A. Human Studies
Year : 2019
Submission ID : 2421382
Source : www.aesnet.org
Presentation date : 12/7/2019 6:00:00 PM
Published date : Nov 25, 2019, 12:14 PM

Authors :
Scott Demarest, Children's Hospital Colorado; Elia Pestane-Knight, Cleveland Clinic; Heather Olson, Boston Children's; Jenny Downs, Telethon Kids Institute; Eric Marsh, MD, PhD; Walter Kaufmann, GGC; Carol-Anne Partridge, CDKL5 UK; Helen Leonard, Telethon

Rationale: Pathological mutations in cyclin-dependent kinase-like 5 cause CDKL5 deficiency disorder (CDD), a genetic syndrome associated with severe epilepsy, cognitive, motor, visual, and autonomic disturbances.  CDD is a relatively common genetic cause of early-life epilepsy.  A specific severity assessment is lacking, required to monitor clinical course, define the natural history, and for clinical trial readiness. Methods: A severity assessment was developed based on clinical and research experience from the International Foundation for CDKL5 Research Centers of Excellence consortium and the NIH Rett and Rett-related disorders Natural History Study consortium.  An initial draft severity assessment was presented and reviewed at the annual CDKL5 Forum meeting (Boston, 2017).  Subsequently it was iterated through four cycles of a modified Delphi process by a group of clinicians, researchers, industry, patient advisory groups, and parents familiar with this disorder until consensus was achieved.  The revised version of the severity assessment was presented for review, comment, and piloting to families at the International Foundation for CDKL5 Research sponsored family meeting (Colorado, 2018).  Final revisions were based on this additional input. Results: The final severity assessment comprised 51 items that comprehensively describe domains of epilepsy, motor, cognition, behavior, vision, speech, and autonomic function.  Parental ratings of therapy effectiveness, child and family functioning are also included. Conclusions: A severity assessment was rapidly developed with input from multiple stake-holders. Refinement through ongoing validation is required for future clinical trials. The consensus methods employed for the development of the severity assessment may be applicable to similar rare disorders. Funding: K12 NS089417, Children’s Hospital Colorado Research Institute, International Foundation for CDKL5 Research,NHMRC #1103745, K23 NS107646-01,U54 HD061222, NHMRC Senior Research Fellowship #1103741, Rett Syndrome Research Trust,Loulou Foundation, Children’s Hospital Colorado Foundation Ponzio Family Chair in Neurology Research
Genetics